The purpose of this study is to compare the effectiveness and potential side effects of an investigational drug called aficamten with the beta-blocker, metoprolol, in people with obstructive hypertrophic cardiomyopathy (oHCM). Obstructive HCM is a condition in which the heart muscle becomes abnormally thickened, which can block the blood flow out of the heart, and the heart muscle works harder to pump blood to the body (increased heart pumping function). Aficamten is designed to reduce heart pumping function. Researchers aim to determine whether aficamten works better than metoprolol in reducing abnormal heart pumping. The effectiveness of both medicines will be compared by measuring participants’ ability to exercise, heart failure symptoms, and the structure of the heart via echocardiogram. Participants will be randomly assigned to receive either aficamten or metoprolol for a total of 24 weeks. They will also be asked to provide biological samples (such as blood or urine). Additionally, researchers will measure the amount of aficamten in the blood at various times, as well as the effect the drug may have on the patient’s oHCM.
What is the full name of this clinical trial?
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy; CY 6032